37 results on '"Rong, Alan"'
Search Results
2. A basket trial design based on constrained hierarchical Bayesian model for latent subgroups
3. Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy
4. Supplementary Figure 1A from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
5. Supplementary Table 1 from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
6. Supplementary Figure Legends from Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
7. An adaptive biomarker basket design in phase II oncology trials
8. An adaptive biomarker basket design in phase II oncology trials.
9. TITE‐gBOIN : Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades
10. Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
11. RAS Mutations in Colorectal Cancer
12. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
13. TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades.
14. Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers.
15. Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect
16. Estimation of delay time in survival data with delayed treatment effect
17. Pattern mixture models for clinical validation of biomarkers in the presence of missing data
18. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate
19. Biomarker threshold adaptive designs for survival endpoints
20. Pattern mixture models for clinical validation of biomarkers in the presence of missing data
21. Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects
22. Additional file 1 of Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy
23. Estimation of delay time in survival data with delayed treatment effect.
24. Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy
25. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
26. The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone.
27. Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial.
28. Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC)
29. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
30. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials
31. PD-0023 Benefit of Adding Panitumumab (pmab) To 1St/2Nd-Line Chemotherapy in Patients with KRAS WT mCRC: A Number-Needed-To-Treat (NNT) Analysis
32. PD-0019 Benefit of Panitumumab (pmab) as Monotherapy in Patients with WT KRAS mCRC: A Number-Needed-To-Treat (NNT) Analysis
33. O-0014 Effect of Post-Protocol anti-EGFR mAb Therapy on Survival Outcomes in Patients with Wild-Type Kras MCRC Treated with Panitumumab Plus Chemotherapy
34. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
35. Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).
36. RAS Mutations in Colorectal Cancer.
37. O-0031EVALUATION OF KRAS, NRAS, AND BRAF MUTATIONS IN PRIME: PANITUMUMAB WITH FOLFOX4 AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.